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Abstract
Background: The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation
performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative
conditioning regimen has been poorly explored.
Methods: We retrospectively analyzed 566 patients who underwent a first HLA-identical allogeneic stem cell
transplantation with this conditioning regimen for acute myeloid leukemia in first complete remission between
2006 and 2013 and compared the outcomes of 145 (25.6%) patients who received ATG (ATG group) to 421 (74.4%)
who did not (no-ATG group). The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional
hazards regression models were used where appropriate.
Results: Patients in the ATG group were older, received more frequently peripheral blood stem cell grafts from
older donors, and were transplanted more recently. With a median follow-up of 19 months, patients in the ATG
group had reduced 2-year cumulative incidence of chronic graft-versus-host disease (GVHD) (31 vs. 52%, p = 0.0002) and
of its extensive form (8 vs. 26%, p < 0.0001) but similar relapse incidence (22 vs. 27%, p = 0.23) leading to improved GVHD
and relapse-free survival (GRFS) (60 vs. 40%, p = 0.0001). In multivariate analyses, the addition of ATG was independently
associated with lower chronic GVHD (HR = 0.46, p = 0.0001), improved leukemia-free survival (HR = 0.67, p = 0.027), overall
survival (HR = 0.65, p= 0.027), and GRFS (HR = 0.51, p = 4 × 10−5). Recipient age above 50 years was the only other factor
associated with worse survivals.
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Conclusions: These results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by
HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant
outcomes due to reduced incidence of chronic GVHD without increased relapse risk.
Keywords: Allogeneic stem cell transplantation, HLA-matched related donor, Acute myeloid leukemia, In vivo T cell
depletion, Graft-versus-host disease, Relapse incidence, GRFS
Background
Allogeneic hematopoietic stem cell transplantation (allo-
SCT) with myeloablative conditioning (MAC) regimen
remains the treatment of choice for intermediate or poor-
risk acute myeloid leukemia (AML) in first complete
remission (CR1) [1]. The standard conditioning regimen
including myeloablative dose of intravenous (iv) busulfan
and cyclophosphamide is however associated with sub-
stantial toxicities in adults above 40 years of age [2]. The
association of fludarabine to myeloablative dose of iv
busulfan (Flu-ivBu4), developed in the past two decades,
has been shown to preserve significant anti-leukemic ac-
tivity with reduced toxicity mortality in both retrospective
[3–8] and prospective randomized studies [9, 10], in par-
ticular, in adults above 40 years. This so-called reduced
toxicity conditioning (RTC) regimen is therefore being
widely used in allo-SCT for patients with AML in CR1.
The Flu-ivBu 4 regimen is usually performed with per-
ipheral blood stem cells (PBSC) to favor engraftment and
enhance the graft-versus-leukemia (GVL) effect [11, 12].
However, use of PBSC from HLA-matched related (MRD)
or unrelated (MUD) donors with MAC increases the risk
of chronic graft-versus-host disease (cGVHD) [11–13].
Prospective randomized studies have shown that in vivo T
cell depletion with anti-thymocyte globulin (ATG) reduces
the incidence of cGVHD without increasing the risk of re-
lapse in allo-SCT performed with PBSC from MRD or
MUD after conventional cyclophosphamide-based MAC
regimens for AML [14–16]. These results raise the ques-
tion of the impact of use of ATG in the Flu-ivBu4 RTC, in
which the balance between the GVH and GVL effects of
allo-SCT might be more sensitive to T cell depletion. Very
scarce data exist on the potential effect of ATG in this
transplant context. Russel et al. reported reduced non-
relapse mortality (NRM) due to lower incidence of
cGVHD in a retrospective study of patients transplanted
with MRD after Flu-Bu-based MAC and ATG compared
to conventional cyclophosphamide-based MAC without
ATG but a trend towards higher relapse incidence [17]. A
Korean study comparing the outcomes of 16 patients re-
ceiving Flu-ivBu for 3 or 4 days and ATG to 45 patients
receiving the same type of conditioning without ATG for
various hematological malignancies transplanted with
MRD did not observe any benefit of adding ATG, with
also concerns about its possible negative impact on
relapse [18]. Heterogeneity in terms of conditioning
between groups or of types of disease limits the interpret-
ation of these data. With the objective to explore the
impact of the use of ATG in the Flu-ivBu4 RTC, we chose
to retrospectively analyze a cohort of 566 adult patients
given hematopoietic stem cells from HLA-identical sibling
donors for AML in CR1 following Flu-ivBu4 conditioning
regimen. In this homogeneous cohort of patients, we
compared post-transplant outcomes of 145 of those who
received ATG for GVHD prophylaxis to the 421 patients
who did not.
Methods
Study design and data collection
This is a retrospective multicenter analysis using the data
set of the Acute Leukemia Working Party (ALWP) of the
European Society of Blood and Marrow Transplantation
(EBMT) group registry. The EBMT is a voluntary working
group of more than 500 transplant centers that are re-
quired to report all consecutive stem cell transplantations
and follow-ups once a year. Audits are routinely per-
formed to determine the accuracy of the data. The
study was planned and approved by the ALWP of the
EBMT. In addition, the study protocol was approved by
the institutional review board at each site and complied
with country-specific regulatory requirements. The
study was conducted in accordance with the Declar-
ation of Helsinki and Good Clinical Practice guidelines.
Since 1990, patients provide informed consent author-
izing the use of their personal information for research
purposes. Eligibility criteria for this analysis included
adult patients above 18 years of age with AML who
underwent a first allo-SCT from an HLA-matched re-
lated donor following fludarabine and 4 days of intra-
venous busulfan (Flu-ivBu4) regimen between 2006 and
2013. Exclusion criteria were previous allogeneic or
cord blood transplantation and ex vivo T cell-depleted
stem cell graft. Variables collected included recipient
and donor characteristics (age, gender, CMV serosta-
tus), disease characteristics and status at transplant,
year of transplantation and interval from diagnosis to
transplantation, transplant-related factors including
conditioning regimen, use and dose of thymoglobulin
as pre-transplant in vivo T cell depletion, stem cell
source (bone marrow (BM) or peripheral blood (PB)),
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post-transplant GVHD prophylaxis. GVHD prophylaxis
regimens were dependent on centers’ protocols. Grad-
ing of acute GVHD was performed using established
criteria [19]. Chronic GVHD was classified as limited
or extensive according to published criteria [20]. For
the purpose of this study, all necessary data were col-
lected according to the EBMT guidelines, using the
EBMT minimum essential data forms. The list of insti-
tutions reporting data included in this study is provided
in the supplemental data (Additional file 1: Table S1).
Statistical analysis
Study end points were engraftment, incidences and se-
verity of acute and chronic GVHD, incidence of primary
disease relapse (RI), NRM, leukemia-free survival (LFS),
overall survival (OS), and GVHD and relapse-free sur-
vival (GRFS). Start time was date of transplant for all
end points. LFS was defined as survival without relapse
or progression, NRM as death without relapse/progres-
sion, and GRFS as survival with no evidence of relapse/
progression, grade III to IV acute graft-versus-host dis-
ease (aGVHD), or severe cGVHD as defined by Ruggeri
et al. for registry-based studies [21]. Cumulative inci-
dence functions (CIF) were used to estimate RI and
NRM in a competing risk setting, because death and re-
lapse compete with each other. For estimating the cu-
mulative incidence of chronic GVHD, we considered
relapse and death to be competing events. Groups were
compared by the chi-square method for qualitative vari-
ables, whereas the Mann-Whitney test was applied for
continuous parameters. Univariate comparisons were
done using the log-rank test for OS, LFS, and GRFS and
the Gray’s test for RI, NRM, and GVHD cumulative inci-
dences. Multivariate analyses were performed using Cox
proportional hazards model for all end points. Factors
differing in terms of distribution between the groups
and all factors known as potentially risk factors were
included in the final model. In order to test for a center
effect, we introduced a random effect or frailty for each
center into the model [22]. All tests were two-sided. The
type I error rate was fixed at 0.05 for the determination
of factors associated with time to event outcomes. Statis-
tical analyses were performed with SPSS 22.0 (IBM
Corp., Armonk, NY, USA) and R 3.2.3 software packages
(R Development Core Team, Vienna, Austria).
Results
Patient, transplant, and disease characteristics
Between 2006 and 2013, 566 patients with AML trans-
planted with a sibling donor following a Flu-ivBu4 myeloa-
blative conditioning regimen with or without ATG were
included in the study. Patient and disease characteristics
are summarized in Table 1. Among the total population of
patients, 421 (74.4%) did not receive ATG within the
conditioning regimen (no-ATG group), while 145 (25.6%)
received ATG (ATG group). Thymoglobulin was the main
ATG brand used (95.2%). Median dose of thymoglobulin
was 5 mg/kg (range, 2.5–15.8), and a majority of patients
(73.7%) received a total dose below 6 mg/kg. Apart from
ATG, GVHD prophylaxis was mainly based on the associ-
ation of cyclosporine (CsA) and methotrexate (MTX) in
the no-ATG group (88.4%), while most of the patients in
the ATG group received CsA alone (29%) or CsA and
MTX (40%). The choice of GVHD prophylaxis was
dependent on the centers’ protocols.
In comparison to the no-ATG group, patients in the
ATG group were older (median age of 48.8 vs. 43.7 years,
p = 0.002), had been transplanted more recently (median
year of transplantation 2012 vs. 2011, p < 10−5), with
older donors (median age of 47 vs. 41 years, p = 0.003),
and were more frequently transplanted with PBSC graft
(93 vs. 80%, p < 10−4) for secondary AML (12 vs. 7%, p =
0.05). There was no difference in terms of cytogenetic
risk between the two groups in patients with available
cytogenetics. Significantly higher proportions of CMV
seropositive patients were transplanted in the no-ATG
group (87 vs. 74%, p < 10−4) resulting in different distri-
butions of transplant CMV risk with increased low risk
in the ATG group (15.5 vs. 8%, p = 0.008) (Table 1).
Impact of ATG on engraftment and GVHD
Engraftment and incidences of acute and chronic
GVHD are shown in Table 2. There was no difference
in terms of engraftment between the no-ATG and ATG
groups (98.6 and 100%, respectively, p = 0.15). Median
time for absolute nuclear cells (ANC) > 0.5 × 109/L was
longer in the no-ATG group (15 and 14 days, respect-
ively, p = 0.001) (Table 2).
In univariate analysis, we did not observe any impact
of the use of ATG on the incidences of grade II–IV and
grade III–IV aGVHD. Day 100 cumulative incidences of
grade II–IV and III–IV aGVHD were similar between
the no-ATG and ATG groups (21.8 vs. 15.3%, p = 0.10
and 7.7 vs. 4.4%, p = 0.19, respectively) (Table 2). By con-
trast, 2-year incidences of overall and extensive chronic
GVHD were significantly reduced in the ATG group in
comparison to the no-ATG group (30.8 vs. 52% for overall
cGVHD, p = 0.0002 and 7.6 vs. 26.3% for extensive cGVHD,
p < 10−4) (Tables 2 and 3 and Fig. 1). As shown in Table 4,
GVHD-related deaths represented 22.2% (n = 32) and
17.1% (n = 6) of all causes of death in the no-ATG and
ATG groups, respectively.
In multivariate analyses, the use of ATG was associated
with a reduced risk of chronic GVHD development (haz-
ard ratio (HR) = 0.46, 95% CI, 0.31–0.68; p = 0.0001)
(Table 5). Factors associated with an increased risk of de-
veloping chronic GVHD were secondary AML (HR = 1.68,
95% CI, 1.04–2.72; p = 0.033) and the use of a female
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Table 1 Patient and disease characteristics
Patient characteristics No-ATG ATG p value
Number of patients 421 145
Recipient age at SCT (years, range) 43.7 (18–68) 48.8 (20–69) 0.002
Recipient gender, n (%) 0.24
Male 215 (51.3%) 82 (56.9%)
Female 204 (48.7%) 62 (43.1%)
Year of SCT (median), year (%) 2011 (2006–2013) 2012 (2006–2013) <10−5
Interval from diagnosis to SCT (median days) 156 156 0.79
Median follow-up a (months, range) 16 (1.5–93) 21 (1–106) 0.81
Donor age (years, range) 41 (8–70) 47 (10–65) 0.003
Donor gender, n (%)
Male 236 (56.3%) 70 (48.6%) 0.11
Female 183 (43.7%) 74 (51.4%)
Female donor to male recipient, n (%) 96 (23%) 44 (30.8%) 0.06
Diagnosis, n (%) 0.05
De novo AML 391 (92.9%) 127 (87.6%)
Secondary AML 30 (7.1%) 18 (12.4%)
Cytogenetics in de novo AML, n (% of available data) 0.60
Good 18 (16.2%) 6 (9%)
Intermediate 76 (68.5%) 50 (74.6%)
Poor 17 (15.3%) 11 (16.4%)
Not available/failed 280 60
Source of SC, n (%) <10−4
BM 84 (20%) 10 (6.9%)
PB 337 (80%) 135 (93.1%)
In vivo T cell depletion, n (%)
Thymoglobuline 0 138 (95.2%)
ATG Fresenius 4 (2.8%)
Missing brand of ATG 3 (2%)
Mean dose of thymoglobuline (mg/kg) (range) 5 (2.5–15.8)
Thymo ≤ 6 mg/kg 98 (73.7%)
Thymo > 6 mg/kg 35 (26.3%)
Unknown dose of thymoglobuline 12
Post-transplant GVHD prophylaxis <10−4
CsA 4 (1%) 42 (29%)
CsA +MTX 372 (88.4%) 57 (39.3%)
CsA/FK 506 + MMF 35 (8.3%) 17 (11.7%)
Other 10 (2.4%) 29 (20%)
Patient positive CMV serology, n (%) 362 (87%) 107 (74.3%) <10−4
Donor positive CMV serology, n (%) 330 (80.1%) 104 (72.7%) 0.07
CMV risk, n (%) 0.008
Low 33 (8%) 22 (15.5%)
Intermediate 328 (77.9%) 103 (71%)
High 49 (12%) 17 (12%)
CMV risk low = negative recipient and donor serology, high positive recipient and negative donor serology, intermediate: all other combinations
AML acute myeloid leukemia, ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, CsA cyclosporine A, MMF mycophenolate mofetil, MTX
methotrexate, PB peripheral blood, SC stem cells, SCT stem cell transplantation
aFor alive patients
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donor for a male recipient (HR = 1.75, 95% CI, 1.27–2.43;
p = 0.001). We observed a center effect on the incidence
cGVHD (p = 0.0007) (Table 5).
Toxicity and NRM
The median follow-up of the entire cohort of 19 months
(range, 1–106) was similar in both no-ATG (16 months)
and ATG groups (21 months) (Table 1). Two-year NRM
for the entire cohort was 15.5% (95% CI, 12.3–19.1). In
univariate analysis, 2-year cumulative incidence of NRM
was no different between the no-ATG (17.3%; 95% CI,
13.3–21.7) and the ATG (10.7%; 95% CI, 7.7–14.2)
groups (p = 0.149). (Table 3 and Fig. 2a).
Apart from GVHD, the main other causes of death
from NRM in the no-ATG and ATG groups were infec-
tions (23 patients and 5 patients (16 and 14.3% of all
deaths), respectively) and veno-occlusive disease (3
patients in each group (3.5 and 8.6% of all deaths), re-
spectively) (Table 4).
In multivariate analyses, recipient age above 50 years
was associated with an increased risk of NRM (HR =
1.83, 95% CI, 1.14–2.94; p = 0.012) and we observed a
center effect on the incidence of NRM (p = 0.047). Al-
though not significant, there was a trend for reduced
NRM in patients receiving ATG (HR = 0.59, 95% CI,
0.32–1.09; p = 0.094) (Table 5).
Use of ATG had no impact on relapse incidence
Two-year cumulative incidence of relapse in the entire
cohort of patients was 25.9% (95% CI, 21.8–30.1) and
represented the main cause of death in the two groups
of patients: 53.4% of all causes of death in the no-ATG
and 54.5% of those of the ATG groups (Table 4). In uni-
variate analysis, the use of ATG had no impact on the 2-
year incidence of relapse, which occurred in 27.2% (95%
CI, 22.4–32.1) of the patients in the no-ATG group and
in 22.5% (95% CI, 15.1–30.8) of those in the ATG group
(p = 0.226) (Table 3 and Fig. 2b). The absence of the
impact of ATG on relapse risk was confirmed in multi-
variate analyses (HR = 0.72, 95% CI, 0.46–1.12; p = 0.149)
(Table 5). No significant factor was associated with the
risk of relapse in this study, although older age
(>50 years) showed a trend to an increased risk (HR =
1.39, 95% CI, 0.96–2.00; p = 0.083).
Use of ATG improved transplant survivals including GRFS
At 2 years, LFS and OS for in the entire cohort of pa-
tients were 58.4% (95% CI, 53.7–63.2) and 62.2% (95%
CI, 57.4–67), respectively. In univariate analysis, 2-year
LFS and OS were improved in the ATG group (66.8%;
95% CI, 58.1–75.6 and 71.8%; 95% CI, 63.4–80.2, re-
spectively) in comparison to the no-ATG group (55.4%;
95% CI, 49.8–61 and 58.9%; 95% CI, 53.2–64.6, respect-
ively) (p = 0.044 and 0.049, respectively) (Table 3 and
Fig. 2c, d). The beneficial impact of ATG on LFS and OS
was confirmed in multivariate analyses (HR = 0.67, 95%
CI, 0.46–0.95, p = 0.027 for LFS and HR = 0.65; 95% CI,
0.44–0.95, p = 0.027 for OS) (Table 5). The only other
factor that also impacted transplant survivals was re-
cipient older age (>50 years) resulting in impaired LFS
(HR = 1.53, 95% CI, 1.15–2.05, p = 0.004) and worse OS
(HR = 1.42, 95% CI, 1.04–1.93, p = 0.026) (Table 5).
Table 2 Engraftment and GVHD
No-ATG ATG p value
Total number of
patients
421 145
Engraftment, n (%) 411 (98.6%) 145 (100%) 0.15
No engraftment,
n (%)
6 (1.4%) 0 (0%)
Missing, n 5 0
Median time ANC
> 0.5 G/L (days, range)
15 (5–45) 14 (5–28) 0.001
Acute GVHD,
Grade 0–I, n (%) 315 (78.2%) 116 (84.7%) 0.10
Grade II–IV, n (%) 88 (21.8%) 21 (15.3%)
Grade III–IV, n (%) 31 (7.7%) 6 (4.4%) 0.19
Missing, n 5 3
Chronic GVHDa
All grades 52% (46–57.7) 30.8% (22.3–39.8) 0.00026
Extensive 26.3% (21.2–31.6) 7.6% (3.5–13.7) 4.7 × 10−5
Limited, n 71 26
Extensive; n 77 8
Missing, n 117 28
ATG anti-thymocyte globulin, GVHD graft-versus-host disease
aTwo-year cumulative incidence
Table 3 Post-transplant 2-year outcomes
NRM RI Extensive GVHD GRFS LFS OS
No-ATG 17.3% [13.3–21.7] 27.2% [22.4–32.1] 26.3% [21.2–31.6] 39.6% [34–45.1] 55.4% [49.8–61] 58.9% [53.2–64.6]
ATG 10.7% [7.7–14.2] 22.5% [15.1–30.8] 7.6% [3.5–13.7] 60.1% [51–69.3] 66.8% [58.1–75.6] 71.8% [63.4–80.2]
p value 0.149 0.226 4.7 × 10−5 0.00016 0.044 0.049
ATG anti-thymocyte globulin, GRFS GVHD and relapse-free survival, LFS leukemia-free survival, NRM non-relapse mortality, OS overall survival, RI relapse incidence
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Two-year overall GRFS was 45.0% (95% CI, 40.1–49.8).
In univariate analysis, patients of the ATG group had im-
proved 2-year GRFS (60.1%, 95% CI, 51–69.3) compared
those of the no-ATG group (39.6%, 95% CI, 34–45.1) (p =
0.00016) (Table 3 and Fig. 3). Use of ATG was significantly
associated with improved GRFS in multivariate analyses
(HR = 0.51, 95% CI, 0.37–0.70, p = 4 × 10−5) (Table 5),
while use of a female donor for a male recipient and re-
cipient older age (>50 years) were associated with worse
GRFS (HR = 1.62, 95% CI, 1.24–2.11, p = 0.0004 and HR =
1.32, 95% CI, 1.02–1.71, p = 0.037) (Table 5).
Discussion
The main challenge of allo-SCT in AML and other
hematological malignancies remains to limit organ life-
threatening toxicity while preserving the GVL effect and
patients’ quality of life by avoiding severe chronic GVHD.
The GVHD and relapse-free survival composite end point
is becoming an important end point to improve in allo-
SCT [21, 23]. In this objective, while improvements in
terms of tolerability of the transplant process have been
shown in the last two decades by the development of re-
duced intensity and toxicity conditioning regimens and by
improvement of supportive care including management of
infections [24], the increased use of PBSC grafts, reaching
70% of stem cell grafts used in Europe nowadays [25], is
also associated with higher incidence of severe cGVHD
even with HLA-identical sibling donors [11, 12, 26], thus
potentially impairing GRFS. The Flu-ivBu4 RTC associated
with PBSC graft has been reported as effective than con-
ventional Bu-cyclophosphamide MAC regimen but with
reduced short- and long-term non-relapse mortality in
AML patients transplanted in CR1 with an HLA 10/10-
matched related or unrelated donor [8–10]. However, the
incidence of chronic GVHD with PBSC (80%) grafts from
HLA-identical sibling donors, following such RTC in the
absence of ATG, remains high with 68% overall cGVHD
and 42% extensive cGVHD incidences at 4 years post-
transplant reported recently by the Spanish Cooperative
Transplant Group [7]. The current study was limited to
AML in CR1 transplanted with HLA-identical donors to
reduce bias due to donor type and disease status on trans-
plant outcomes. As reported in other contexts of allo-SCT
[14, 16, 17, 27–30], we confirm in the present study that
the addition of intermediate dose of thymoglobulin (me-
dian, 5 mg/kg) significantly reduces, after adjustment to
other factors, the risk of developing cGVHD (Cox HR=
0.46, p = 0.0001). Compared to patients not receiving
ATG, those transplanted with ATG, despite having re-
ceived more frequently PBSC, had a reduction of 2 years
of cumulative incidence of the overall cGVHD from 52
to 31% (p = 0.00026) and that of extensive cGVHD
from 26 to 8% (p < 10−4). Such reduction of cGVHD
incidence was not associated with reduced anti-
leukemic control since use of ATG did not impact
a b
Fig. 1 Cumulative incidence of chronic GVHD according to the use of ATG. a Overall incidence of chronic GVHD and b incidence of extensive
chronic GVHD in the ATG and no-ATG groups as mentioned
Table 4 Causes of death
No-ATG ATG
N = 144 N = 35
Relapse 77 (53.5%) 19 (54.3%)
GVHD 32 (22.2%) 6 (17.1%)
Infection 23 (16%) 5 (14.3%)
VOD 5 (3.5%) 3 (8.6%)
Idiopathic pneumonia 2 (1.4%) 0 (0%)
Hemorrhage 2 (1.4%) 0 (0%)
Other SCT-related 3 (2.1%) 2 (5.7%)
ATG anti-thymocyte globulin, GVHD graft-versus-host disease, SCT stem cell
transplantation, VOD veno-occlusive disease
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relapse incidence in this series of AML transplanted in
CR1 in both univariate and multivariate analyses. Most
patients had received a thymoglobulin dose of <6 mg/
kg, so we could not analyze the impact of the ATG dose
on outcomes. However, these results are in line with
preserved GVL effect despite the addition of low or inter-
mediate doses of ATG in the context of allo-SCT for AML
performed with MRD and MUD following conventional
MAC [31, 32] and RIC [29, 30, 33, 34], in contrast with in-
creased risk of relapse with doses of thymoglobulin
>10 mg/kg [28].
By contrast, as reported by others [15, 17, 30], we did
not observe protective effect of such doses of ATG
against acute GVHD. Actually, in the context of allo-
SCT performed with PBSC from matched related or un-
related donors, use of low doses of ATG (2.5 mg/kg of
thymoglobulin) was associated with an increased risk of
aGVHD [34, 35]; a reduction of the incidence of aGVHD
has been observed with thymoglobulin doses starting at
5 mg/kg, although higher doses (≥7.5 mg/kg of thymo-
globulin) were associated with increased risk of mortality
from infections and relapse in both MAC and RIC
a b
c d
Fig. 2 Transplant outcomes according to the use of ATG. Cumulative incidence of non-relapse mortality (NRM) (a), of relapse (b), leukemia-free
survival (c), and overall survival (d) in the ATG and no-ATG groups as mentioned
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settings [28, 36]. The optimal dose of thymoglobulin in
both RIC and MAC seems therefore to be about 5 mg/
kg. At such intermediate dose of ATG, as described by
others [14, 15, 30, 37], we did not observe difference of
infection-related mortality between the ATG and no-
ATG groups, despite potential increased frequency of viral
EBV reactivation manageable by viral load monitoring and
preemptive use of rituximab [30, 37].
Altogether, our results show that the addition of inter-
mediate dose of ATG to the Flu-ivBu4 RTC represents an
independent factor associated with improved GRFS, as de-
fined by Ruggeri et al. for registry-based studies [21],
allowing a probability of being alive without disease and
without significant cGVHD at 2 years after allo-SCT in
60% of the patients transplanted for AML in CR1 with a
sibling donor, compared to 40% of those not receiving
ATG. Although GRFS is not routinely analyzed up to
now, a 2-year 60% GRFS compares favorably to 40% GRFS
at 3 years reported after allo-SCT performed for AML
transplanted in CR1 (79%) or CR2 (21%) with MAC (61%)
or RIC and PBSC (82%) from HLA-matched related (55%)
or unrelated (45%) donors within the EBMT registry [21],
and to 25% at 1 year reported with PBSC HLA-sibling
donor allo-SCT by the Minnesota Group [23].
Use of ATG in our series appears also as an independ-
ent factor associated with improved LFS and OS, mainly
due to reduced incidence of overall and extensive
cGVHD leading to a trend towards increased late NRM
in the absence of ATG. Although a center effect was ob-
served in the incidence of cGVHD and NRM, possibly
due to preferential used of ATG and of prophylactic
donor lymphocyte infusion in some centers, we did not
detect a center effect on LFS, OS, and GRFS. The only
other factor associated with worse survivals was recipi-
ent age above 50 years, due to higher NRM, as reported
by others with such conditioning regimen [7].
Conclusions
We recognize that this study has several limitations,
mainly because of its retrospective aspect and that the
reason for the choice of GVHD prophylaxis was not
known but mainly dependent on the center’s protocols.
However, the study was performed on a homogeneous
cohort of AML patients transplanted in CR1 with HLA-
identical sibling donors following a Flu-ivBu4 RTC. Des-
pite these limitations, the results of this study suggest
that, in this particular setting, an intermediate dose of
ATG improves the composite end point severe GVHD
and relapse-free survival by reducing the incidence of
overall and chronic GVHD without affecting the long-
term anti-leukemic effect. These results should be con-
firmed in a well-designed phase III randomized trial.
Fig. 3 GRFS according to the use of ATG
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